About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases.

News

November 9, 2018
Caladrius Biosciences to Participate in the Inv€$tival Showcase in Partnership with Jefferies and the Jefferies 2018 London Healthcare Conference

November 8, 2018
Caladrius Biosciences Reports 2018 Third Quarter Financial Results

November 8, 2018
Caladrius Biosciences Appoints Cynthia Schwalm to Board of Directors

Events

November 8, 2018
Third Quarter 2018 Financial Results Call

October 4, 2018
2018 Cell and Gene Meeting on the Mesa – Partnering Forum

September 5, 2018
Caladrius Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

T Regulatory Cell Technology

CD34 Cell Technology

CD34 Cell Technology